Repligen (NASDAQ:RGEN) Given New $180.00 Price Target at HC Wainwright

Repligen (NASDAQ:RGEN) had its price objective decreased by HC Wainwright from $240.00 to $180.00 in a report released on Thursday morning,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

Several other analysts also recently weighed in on the stock. Wolfe Research initiated coverage on shares of Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Canaccord Genuity Group initiated coverage on shares of Repligen in a research report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. Royal Bank of Canada reaffirmed an “outperform” rating and set a $205.00 price objective on shares of Repligen in a report on Thursday, September 26th. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Finally, StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Friday, January 3rd. Six investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, Repligen presently has a consensus rating of “Moderate Buy” and an average price target of $184.73.

Repligen Stock Performance

Shares of RGEN stock opened at $167.90 on Thursday. The company has a market cap of $9.41 billion, a P/E ratio of -453.77, a PEG ratio of 4.51 and a beta of 0.97. The firm has a fifty day moving average price of $149.49 and a 200 day moving average price of $145.57. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $113.50 and a 12 month high of $211.13.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same period in the prior year, the firm posted $0.23 EPS. The business’s quarterly revenue was up 9.7% compared to the same quarter last year. Sell-side analysts predict that Repligen will post 1.54 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

A number of hedge funds and other institutional investors have recently bought and sold shares of RGEN. Champlain Investment Partners LLC raised its position in Repligen by 149.0% during the 3rd quarter. Champlain Investment Partners LLC now owns 1,420,935 shares of the biotechnology company’s stock worth $211,464,000 after buying an additional 850,345 shares during the last quarter. DF Dent & Co. Inc. lifted its holdings in shares of Repligen by 31.0% in the 3rd quarter. DF Dent & Co. Inc. now owns 590,321 shares of the biotechnology company’s stock valued at $87,852,000 after buying an additional 139,615 shares during the period. Dimensional Fund Advisors LP boosted its stake in shares of Repligen by 39.4% in the second quarter. Dimensional Fund Advisors LP now owns 429,524 shares of the biotechnology company’s stock valued at $54,149,000 after buying an additional 121,305 shares in the last quarter. Two Sigma Advisers LP grew its holdings in Repligen by 421.9% during the third quarter. Two Sigma Advisers LP now owns 126,300 shares of the biotechnology company’s stock worth $18,796,000 after acquiring an additional 102,100 shares during the period. Finally, Fred Alger Management LLC raised its position in Repligen by 29.5% in the third quarter. Fred Alger Management LLC now owns 398,554 shares of the biotechnology company’s stock worth $59,313,000 after acquiring an additional 90,831 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.